Discovery of GH2616, a potent and selective KIF18A inhibitor with robust in vivo efficacy in p53 mutant cancer

被引：1
|
作者：
Li, Jie Jack
Zhang, Guiping
Li, Jiapeng
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-4482
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4482
引用
收藏
页数：2
相关论文
共 15 条
  • [1] ZM-412, a potent and selective KIF18A inhibitor with robust efficacy as monotherapy in CIN-positive tumors and in combination with MMAE-conjugated ADC in CIN-negative tumors
    Zhou, Feng
    Zhou, Lei
    Wang, Ruina
    Xue, Liting
    Qin, Xiaokang
    Li, Zhengtao
    Yu, Jian
    Tang, Renhong
    CANCER RESEARCH, 2024, 84 (06)
  • [2] Imino-tetrahydro-benzothiazole derivatives as p53 inhibitors:: Discovery of a highly potent in vivo inhibitor and its action mechanism
    Pietrancosta, Nicolas
    Moumen, Anice
    Dono, Rosanna
    Lingor, Paul
    Planchamp, Veronique
    Lamballe, Fabienne
    Baehr, Mathias
    Kraus, Jean-Louis
    Maina, Flavio
    JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (12) : 3645 - 3652
  • [3] Gene Therapy with p14/tBID Induces Selective and Synergistic Apoptosis in Mutant Ras and Mutant p53 Cancer Cells In Vitro and In Vivo
    Fine, Robert L. L.
    Mao, Yuehua
    Garcia-Carracedo, Dario
    Su, Gloria H. H.
    Qiu, Wanglong
    Hochfeld, Uri
    Nichols, Gwen
    Li, Yong-Liang
    Dinnen, Richard D.
    Raffo, Anthony
    Brandt-Rauf, Paul W. W.
    BIOMEDICINES, 2023, 11 (02)
  • [4] Discovery of CRD1601, a potent and selective HPK1 inhibitor with robust in vivo anti-cancer activity
    Banerjee, Monali
    Shrivastava, Ritesh
    Pryde, David
    Middya, Sandip
    Debnath, Sabyasachi
    Middya, Anindita
    Yadav, Dharmendra
    Rawat, Nidhi
    Ghosh, Rajib
    Padaliya, Manisha
    Basu, Sourav
    Surya, Arjun
    CANCER RESEARCH, 2024, 84 (06)
  • [5] The deubiquitinase inhibitor WP1130 drives nuclear aggregation and reactivation of mutant p53 for selective cancer cell targeting
    Oak, Swapnil
    Karajgikar, Onkar
    Gadewal, Nikhil
    Sulkshane, Prasad
    Verma, Tripti
    Gupta, Sanjay
    Teni, Tanuja
    FEBS JOURNAL, 2025,
  • [6] NVP-HDM201: cellular and in vivo profile of a novel highly potent and selective PPI inhibitor of p53 Mdm2
    Jeay, Sebastien
    Chene, Patrick
    Ferretti, Stephane
    Furet, Pascal
    Gruenenfelder, Bjoern
    Guagnano, Vito
    Guerreiro, Nelson
    Halilovic, Ensar
    Hofmann, Francesco
    Kellen, Joerg
    Leonard, Michelle
    Mah, Robert
    Masuya, Keiichi
    Ramos, Rita
    Rynn, Caroline
    Ruetz, Stephan
    Stachyra-Valat, Therese
    Stutz, Stefan
    Vaupel, Andrea
    Wuerthner, Jens
    Holzer, Philipp
    CANCER RESEARCH, 2016, 76
  • [7] The Chk1 inhibitor AZD7762 sensitises p53 mutant breast cancer cells to radiation in vitro and in vivo
    Ma, Zhikun
    Ya, Guoliang
    Zhou, Bo
    Fan, Yonggang
    Gao, Shegan
    Feng, Xiaoshan
    MOLECULAR MEDICINE REPORTS, 2012, 6 (04) : 897 - 903
  • [8] Discovery of a novel, potent and selective small-molecule inhibitor of PD-1/PD-L1 interaction with robust in vivo anti-tumour efficacy
    Liu, Chenglong
    Zhou, Feilong
    Yan, Ziqin
    Shen, Lian
    Zhang, Xichen
    He, Fenglian
    Wang, Heng
    Lu, Xiaojie
    Yu, Ker
    Zhao, Yujun
    Zhu, Di
    BRITISH JOURNAL OF PHARMACOLOGY, 2021, 178 (13) : 2651 - 2670
  • [9] Discovery of JN122, a Spiroindoline-Containing Molecule that Inhibits MDM2/p53 Protein-Protein Interaction and Exerts Robust In Vivo Antitumor Efficacy
    Cheng, Jing
    Yan, Ziqin
    Jiang, Kailong
    Liu, Chen
    Xu, Dehua
    Lyu, Xilin
    Hu, Xiaobei
    Zhang, Shiyan
    Zhou, Yubo
    Li, Jia
    Zhao, Yujun
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (24) : 16991 - 17025
  • [10] The histone deacetylase inhibitor FK228 increases the efficacy of adenovirus-mediated p53 family gene therapy in in vitro and in vivo human cancer models
    Sasaki, Y
    Oshima, Y
    Mita, H
    Naishiro, Y
    Toyota, M
    Imai, K
    Tokino, T
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 231S - 231S
12